Effect of Tumor Necrosis Factor on the Antitumor Efficacy and Toxicity of Aminopterin-Monoclonal Antibody Conjugates: Parameters for Optimization of Therapy

Cancer Research

Volumn 50, Issue 18, 1990, Pages 6028-6033

  Russell, S M ^a   Krauer, K G ^a   McKenzie, I F C ^a   Pietersz, G A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPTERIN; IMMUNOCONJUGATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY LABELING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

AMINOPTERIN; ANIMAL; ANTIBODIES, MONOCLONAL; AUTORADIOGRAPHY; IMMUNOTOXINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR;

EID: 0025089252     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Tjandra, J. J., Pietersz, G. A., Teh, J. G., Cuthbertson, A. M. M., Sullivan, J. R., and McKenzie, I. F. C. Phase I clinical trial of drug-monoclonal antibody conjugates in patients with advanced colorectal carcinoma-a preliminary report. Surgery, 106: 533–545, 1989.
2. Takahashi, T., Yamaguchi, T., Kitamura, K., Suzuyama, H., Honda, M., Yakota, T., Kotanagi, H., Takahashi, M., and Hashimoto. Y. Clinical application of monoclonal antibody-drug conjugates for immunotargeting chemotherapy of colorectal carcinoma. Cancer (Phila.), 61: 881–888, 1988.
3. Spitler, L. E., del Rio, M., Khentigan, A., Wedel, N. I., Brophy, N. A., Miller, L. L., Harkonen, W. I., Rosendorf, L. L., Lee, H. M., Mischak, R. P., Kawahata, R. T., Staudemine, J. B., Fradkin, L. B., Bautista, E. E., and Scannan, P. J. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res., 47: 1717–1724, 1987.
4. Kanellos, J., McKenzie, I. F. C., and Pietersz, G. A. In vivo studies of whole-ricin monoclonal antibody immunoconjugates for the treatment of murine tumors. Immunol. Cell Biol., 66: 403–415, 1988.
5. Kanellos, J., Pietersz, G. A., and McKenzie, I. F. C. Intratumour therapy of solid tumors with ricin-antibody conjugates. Immunol. Cell. Biol., 67: 89–99, 1989.
6. Smyth, M. J., Pietersz, G. A., and McKenzie, I. F. C. Increased antitumor effect of immunoconjugates and tumor necrosis factor in vivo. Cancer Res., 48: 3607–3612, 1988.
7. Smyth, M. J., Pietersz, G. A., Classon, B. J., and McKenzie, I. F. C. Specific targeting of chlorambucil to tumors with the use of monoclonal antibodies. J. Natl. Cancer Inst., 76: 503–510, 1986.
8. Hogarth, P. M., Edwards, J., McKenzie, I. F. C., Goding, J. W., and Liew, F. Y. Monoclonal antibodies to murine Ly-2.1 cell surface antigen. Immunology, 46: 135–144, 1982.
9. Kanellos, J., Pietersz, G. A., Cunningham, Z., and McKenzie, I. F. C. Antitumor activity of aminopterin monoclonal antibody conjugates; in vivo and in vitro comparison with methotrexate-monoclonal antibody conjugates. Immunol. Cell Biol., 65:483–493, 1987.
10. Bradford, M. M. A rapid and sensitive method of quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal. Biochem., 72: 248–253, 1976.
11. Pietersz, G. A., Kanellos, J., Smyth, M. J., Zalcberg, J., and McKenzie, I. F. C. The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer. Immunol. Cell Biol., 65: 111–125, 1987.
12. Jain, R. K. Determinants of tumor blood flow: a review. Cancer Res., 48: 2641–2658, 1989.
13. Alexander, R. B., Isaacs, J. T., and Coffey, D. S. Tumor necrosis factor enhances the in vitro and in vivo efficacy of chemotherapeutic drugs targeted at DNA topoisomerase II in the treatment of murine bladder cancer. J. Urol., 138:427–429, 1987.
14. Regenass, U., Miiller, M., Curschellas, E., and Matter, A. Anti-tumor effects of tumor necrosis factor in combination with chemotherapeutic agents. Int. J. Cancer, 39: 266–273, 1987.
15. Creasey, A. A., Doyle, L. V., Reynolds, M. T., Jung, T., Lin, L. S., and Vitt, C. R. Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines. Cancer Res., 47: 145–149, 1987.
16. Beutler, B., and Cerami, A. Cachectin: more than a tumor necrosis factor. N. Engl. J. Med., 316: 379–385, 1987.
17. MacPherson, G. G., and North, R. J. Endotoxin-mediated necrosis and regression of established tumors in the mouse. A correlative study of quantitative changes in blood flow and ultrastructural morphology. Cancer Immunol. Immunother., 21: 209–216, 1986.
18. Shimomura, K., Manda, T., Mukumoto, S., Kobayashi, K., Nakano, K., and Mori, J. Recombinant human tumor necrosis factor-α: thrombus formation is a cause of anti-tumor activity. Int. J. Cancer., 41: 243–247, 1988.
19. Scheinberg, D. A., and Strand, M. Kinetic and catabolic considerations of monoclonal antibody targeting in erythroleukemic mice. Cancer Res., 43: 265–272, 1983.